Pharmaceutical composition comprising chito-oligomers
AssigneeGenis Ehf
InventorsJohannes GISLASON, Martin Peter, Jon M. Einarsson, Sven Bahrke
Life of this patent
Estimating the term…
Abstract
Compositions are provided comprising chito-oligomers obtainable from chitin, comprising oligomers of N-acetyl glucosamine (NAG) and glucosamine, wherein at least 50% of the oligomers have a chain length of about 2-50, and the degree of deacetylation of the oligomers is in the range of about 0-70%, preferably about 30-50%. The compositions are highly useful as pharmaceutical compositions for treatment of joint disorders such as rheumatoid arthritis and osteoarthritis. Also provided are methods for treatment of joint disorders and treatment against inflammatory activity.
Claims6
1-14. (canceled)
A pharmaceutical composition for treatment of disorders selected from the group containing joint disorders including osteoarthritis and rheumatoid arthritis, inflammatory disorders, and other rheumatoid conditions comprising chito-oligomers of N-acetyl glucosamine (NAG) and glucosamine wherein the chain length of the chito-oligomers is in the range of about 2-50, and wherein the degree of deacetylation is in the range of about 0-70%.
A pharmaceutical composition for anti-inflammatory treatment and treatment of joint disorders comprising water-soluble partially deacetylated chitin with a degree of deacetylation in the range of about 35 to about 50%.
Dependencies are inferred from the claim text.